MIB Agents OsteoBites and osTEAo

MIB Agents Osteosarcoma
  • 5.0 (5)
  • Medicine
  • Updated Weekly

Each week, MIB Agents talks with the leaders and innovators in osteosarcoma surgery, research, treatment and advocacy. Questions are taken during the webinar and are included in each podcast. More information is available at www.mibagents.org

  1. 7h ago

    osTEAo: Same Summer, Different View

    This episode of osTEAo features OsteoWarriors Inaaya, Sloane, and Elise sharing their experiences adapting summer activities and travel with limb differences. They discuss everything from summer camp, swimming, and ziplining to navigating theaters, airports, and public transportation. The conversation also explores accessibility, disability rights, advocating for accommodations, and finding new ways to enjoy activities after cancer. Listen in for honest stories, helpful tips, and a look at how they’re making summer adventures their own.

  2. 6d ago

    Dissecting and Targeting Metastatic Drivers in Osteosarcoma

    Metastatic osteosarcoma remains a major clinical challenge, highlighting the need to better understand the molecular mechanisms that drive disease progression. In this talk, Moreno will present the use of an in vivo CRISPR interference (CRISPRi) screen to identify genes that promote osteosarcoma progression. She will focus on KLF5, a transcription factor that emerged as a key regulator in our studies, and discuss its potential as a therapeutic target for osteosarcoma. Marta Roman Moreno, PhD, is a postdoc fellow in the Sweet-Cordero Lab at UCSF. She has a BSc in Biochemistry from the University of Granada in Spain, and an MSc and PhD in Biomedical Research from the University of Navarra (Spain). The key focus of her work is to define key regulators of metastasis in osteosarcoma and determine the vulnerabilities that can diminish the survival of metastatic cells. Using mouse models, cell lines derived from patient samples (PDXs) and pooled in vivo CRISPR screens, she has been able to identify several potential genetic vulnerabilities in the context of metastatic osteosarcoma.

  3. Aug 10

    Validation of MCL1 inhibition and combinatorial therapy for elimination of osteosarcoma lung metastasis

    Dr. Alexander Davies discusses his OutSmarting Osteosarcoma-funded work on the validation of MCL1 inhibition and combinatorial therapy for elimination of osteosarcoma lung metastasis, funded Because of Matthew, in partnership with Fishin' for the Cure.

  4. Aug 3

    Combinatorial immunotherapy to overcome cellular therapy resistance in osteosarcoma

    Osteosarcoma Webinar Series: Jeremy Rosenblum, MD from New York Medical College will discuss his work on combinational next generation CAR NK immunotherapy in osteosarcoma. Immunotherapeutic approaches to treating osteosarcoma have had limited success to date. Using natural killer cells as the base platform, our group seeks to combine immunotherapies to cure osteosarcoma. The presentation will describe projects using chimeric antigen receptor natural killer (CAR-NK) cells together with monoclonal antibodies, as well as a newly funded project modifying CAR-NK cells to be able to overcome the immunosuppressive osteosarcoma tumor microenvironment.

  5. Jul 24

    Epigenetic Regulation of the Type I Interferon Pathway in Osteosarcoma: Implications for Immune Checkpoint Blockade

    Osteosarcoma Webinar Series: Dr. Jing Huang is a Senior Investigator and Head of the Cancer and Stem Cell Epigenetics Group in the Laboratory of Cancer Biology and Genetics at the National Cancer Institute (NCI). He received his bachelor’s degree in Biochemistry from Peking University and his Ph.D. in Biochemistry and Biophysics from the University of Rochester, followed by postdoctoral training in cancer epigenetics at the Wistar Institute. Dr. Huang joined the NCI as a Principal Investigator in 2008 and earned tenure in 2016. His laboratory investigates transcriptional and epigenetic regulation in cancer and stem cells, with a major focus on the oncogenic driver RUNX2 in osteosarcoma. His ultimate goal is to develop novel therapeutic strategies and translate laboratory discoveries into clinical advances for osteosarcoma patients.

  6. Jul 16

    osTEAo: Live from FACTOR '26!

    Recorded live at FACTOR 2026, this episode of osTEAo features conversations with OsteoWarriors, OsteoSiblings, parents and family members, as well as the behind-the-scenes volunteers and staff who help make FACTOR possible. Guests share their experiences, favorite memories, and what this community means to them, offering a glimpse into the connection, support, and sense of belonging that define the annual conference. This in-person recording offers a look at the people and moments that make FACTOR and osTEAo so important.

  7. Jun 18

    osTEAo: Advocacy Doesn't End at Discharge

    In this episode of osTEAo, Sammy and Inaaya are joined by Elise, Sloane, and Camille for a conversation about self-advocacy and how it evolves after an osteosarcoma diagnosis. The group shares personal experiences navigating college, careers, travel, accessibility, and everyday life as survivors and individuals with disabilities. From campus accommodations to airport encounters, they discuss the challenges of speaking up for their needs, finding supportive communities, and learning how to navigate a world that isn't always built with accessibility in mind.

  8. Jun 5

    Your Story, Your Tissue, Your Impact: Changing the Future of Osteosarcoma

    Osteosarcoma Webinar Series: Barbara VanHare from the Rare Cancer Research Foundation will discuss the key role patients can play in accelerating Osteosarcoma breakthroughs through the donation of excess tissue and clinical data. She will walk through current barriers in rare cancer research, why each patient's story and tissue is important and cover the different ways to participate, all at no cost to the patient or their families.

See All (225)

Ratings & Reviews

5
out of 5
5 Ratings

About

Each week, MIB Agents talks with the leaders and innovators in osteosarcoma surgery, research, treatment and advocacy. Questions are taken during the webinar and are included in each podcast. More information is available at www.mibagents.org

Information